Market news

Omnicell trades around US$33.17 after a mixed share price record, and the key issue now is whether that level lines up with the cash the business can generate over time. With the stock showing both long slumps and shorter rebounds, investors are left asking how closely the current market value tracks the company’s underlying cash flows. Over the past 5 years the share price has fallen 77.7%, which puts the spotlight firmly on whether the long term cash flow potential still supports today’s...

TraceLink, the world's largest Agentic Business Network for the life sciences and healthcare supply chain, today announced an integration between its Drug Supply Chain Security Act (DSCSA) compliance solution and the pharmacy inventory management systems of Omnicell, Inc. (Nasdaq: OMCL), a leading healthcare technology provider focused on empowering autonomous medication management. This integration is expected to enable hospitals and health systems to manage product verification, traceability,

FORT WORTH, Texas, August 31, 2026--Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference

Nnamdi Njoku's disposal reduced his direct holdings by 4%, with over half tied to tax withholding from RSU vesting. He retains ~161,223 shares worth $5.81 million.

OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.

Detailed price information for Omnicell Inc (OMCL-Q) from The Globe and Mail including charting and trades.

In the past quarter, Omnicell, Inc. reported second-quarter 2026 revenue of US$312.21 million and net income of US$24.29 million, with both basic and diluted earnings per share from continuing operations rising compared with a year earlier, and also showed improved profitability for the first half of 2026. Omnicell also raised its full-year 2026 revenue guidance to a range of US$1.23 billion to US$1.25 billion and projected third-quarter 2026 revenue of US$301 million to US$307 million,...

Omnicell stock is currently caught between two different valuation signals. The Discounted Cash Flow (DCF) estimate points to meaningful upside to intrinsic value, while market-based multiples suggest the shares already trade at a premium. Over the past 5 years Omnicell shareholders have seen the share price fall 77.6%, which sets a cautious backdrop for any claim that the stock now offers clear value. Recent product work at subsidiary EnlivenHealth, such as the VaxReach program to support...

In the past quarter, Omnicell, Inc. reported second-quarter 2026 revenue of US$312.21 million and net income of US$24.29 million, with both basic and diluted earnings per share from continuing operations rising compared with a year earlier, and also showed improved profitability for the first half of 2026. Omnicell also raised its full-year 2026 revenue guidance to a range of US$1.23 billion to US$1.25 billion and projected third-quarter 2026 revenue of US$301 million to US$307 million,...

Detailed price information for Omnicell Inc (OMCL-Q) from The Globe and Mail including charting and trades.

Detailed price information for Omnicell Inc (OMCL-Q) from The Globe and Mail including charting and trades.

Omnicell (OMCL) reported Q2 non-GAAP net income Thursday of $0.94 per diluted share, up from $0.45 a

Omnicell (OMCL) delivered earnings and revenue surprises of +95.83% and +0.83%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

FORT WORTH, Texas, July 30, 2026--Omnicell Announces Second Quarter 2026 Financial Results

Omnicell (NASDAQ:OMCL) reported second-quarter 2026 revenue at the high end of its prior outlook and profitability above expectations, while widening its full-year product bookings range to reflect uncertainty in the timing of customer purchasing decisions for large medication-management platform in

Omnicell Inc (OMCL) delivers solid Q2 results with a $15 million tariff refund boosting EPS, but faces headwinds from lengthening sales cycles and a wide bookings guidance range.

Healthcare tech company Omnicell (NASDAQ:OMCL) will be announcing earnings results this Thursday morning. Here’s what investors should know.

OMCL heads into Q2 earnings with OmniSphere adoption, Connected Devices execution and recurring revenue growth ahead of July 30 results.

Detailed price information for Argenx Se ADR (ARGX-Q) from The Globe and Mail including charting and trades.

FORT WORTH, Texas, July 13, 2026--Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026

Earlier this month, Omnicell filed a US$72.384 million shelf registration for 1,600,000 common shares tied to an ESOP-related offering and elevated Chief Operating Officer Nnamdi Njoku to President, while Randall Lipps remained Chief Executive Officer and Chairman. This combination of leadership evolution and employee-focused equity issuance may influence how investors assess Omnicell’s governance, culture, and long-term execution capacity. We’ll now examine how Njoku’s expanded leadership...

OMCL's autonomous pharmacy strategy, SaaS growth and global expansion boost shares. Can rising costs and tariffs slow the momentum?

Detailed price information for Annexon Inc (ANNX-Q) from The Globe and Mail including charting and trades.